318 results
Page 4 of 16
6-K
EX-99.1
n8nemx5 xg
18 Apr 16
First-HD Study shows improvements in Total Motor Score and Swallowing Function in Huntington disease patients treated with SD-809
12:00am
6-K
EX-99.1
riz9qzb
12 Apr 16
Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual Meeting
12:00am
6-K
EX-99.1
fk7nb45ilzjgo3 iay
30 Sep 15
IMPORTANT NEW DATA FROM TEVA’S TEV-48125 PHASE 2b MIGRAINE PROGRAM PUBLISHED INLANCET NEUROLOGYIN BACK-TO-BACK ARTICLES
12:00am
6-K
EX-99.1
eiej47pz
28 Sep 15
Teva Announces Approval of COPAXONE® in Japan for the Prevention of Relapse of Multiple Sclerosis
12:00am
6-K
EX-99.1
9y93tpxw2r37p
27 Jul 15
Teva to Acquire Allergan Generics for $40.5 Billion
12:00am
6-K
EX-99.1
ynfgfrkycvpf1c7
23 Mar 15
Live Filing
12:00am
6-K
EX-99.1
uj40pt19syd8zbfh5wr
25 Feb 15
Live Filing
12:00am
6-K
EX-99.1
ghmyz8
24 Feb 15
TEVA ANNOUNCES POSITIVE RESULTS FOR TEV-48125 IN PHASE IIb CHRONIC MIGRAINE STUDY MEETING PRIMARY AND SECONDARY ENDPOINTS
12:00am
6-K
EX-99.1
bzlj1
23 Feb 15
Live Filing
12:00am
6-K
EX-99.1
ame jws9cgm7xd7eef
20 Feb 15
Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
12:00am
6-K
EX-99.1
87s6gyspy dad28me
20 Jan 15
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE®20 mg/mL Case and Remand for Further Review
12:00am
6-K
EX-99.1
3grz5d4
23 Dec 14
Live Filing
12:00am
6-K
EX-99.1
mpirvhj5ii zcpw
19 Dec 14
First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age
12:00am
6-K
EX-99.1
8bkx2r o5
4 Dec 14
Live Filing
12:00am
6-K
EX-99.1
s3935f20wb5js olvz
18 Nov 14
Live Filing
12:00am
6-K
EX-99.1
35tg9odqtb
7 Nov 14
Late Stage Data to be Presented at ACAAI 2014
12:00am
6-K
EX-99.1
4crmvf2u5 ftbhox
7 Nov 14
Live Filing
12:00am